MIRATI THERAPEUTICS INC's ticker is MRTX and the CUSIP is 60468T105. A total of 290 filers reported holding MIRATI THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.39 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $139,372 | +109.3% | 3,200 | +74.2% | 0.00% | – |
| Q2 2023 | $66,588 | -6.0% | 1,837 | -3.6% | 0.00% | – |
| Q1 2023 | $70,811 | -29.3% | 1,905 | -15.0% | 0.00% | – |
| Q4 2022 | $100,220 | -4.6% | 2,240 | +47.5% | 0.00% | – |
| Q3 2022 | $105,000 | +6.1% | 1,519 | +2.9% | 0.00% | – |
| Q2 2022 | $99,000 | +90.4% | 1,476 | +129.2% | 0.00% | – |
| Q1 2022 | $52,000 | +79.3% | 644 | +211.1% | 0.00% | – |
| Q4 2021 | $29,000 | -66.7% | 207 | -57.6% | 0.00% | – |
| Q3 2021 | $87,000 | +74.0% | 488 | +57.4% | 0.00% | – |
| Q2 2021 | $50,000 | -15.3% | 310 | -10.9% | 0.00% | – |
| Q1 2021 | $59,000 | -19.2% | 348 | +3.9% | 0.00% | – |
| Q4 2020 | $73,000 | -3.9% | 335 | -26.2% | 0.00% | – |
| Q3 2020 | $76,000 | +94.9% | 454 | +31.2% | 0.00% | – |
| Q2 2020 | $39,000 | +39.3% | 346 | -98.3% | 0.00% | – |
| Q1 2020 | $28,000 | – | 20,726 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aviva Holdings Ltd. | 3,135,966 | $136,602,679 | 87.83% |
| EcoR1 Capital, LLC | 5,748,399 | $250,400,260 | 8.45% |
| Boxer Capital, LLC | 3,201,440 | $139,454,726 | 7.42% |
| RTW INVESTMENTS, LP | 6,768,514 | $294,836,470 | 6.22% |
| Paradigm Biocapital Advisors LP | 1,668,116 | $72,663,133 | 4.93% |
| Avoro Capital Advisors LLC | 6,666,666 | $290,399,971 | 4.53% |
| Octagon Capital Advisors LP | 655,051 | $28,534,022 | 4.38% |
| Artal Group S.A. | 2,024,226 | $88,175 | 3.78% |
| Ally Bridge Group (NY) LLC | 70,283 | $3,061,527 | 3.59% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 216,000 | $9,404,640 | 3.17% |